We hypothesize that specific antibodies targeting MUC16 and CD16 can increase the distance between MUC16 and the MUC16 receptor on NK cells by recognizing the MUC16 antibody on tumor cells and the CD16 antibody on NK cells respectively, so that the NK cells can function normally. Here, MUC16 is linked to neoplasm.